Osimertinib making a breakthrough in lung cancer targeted therapy
Haijun Zhang Department of Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing, People’s Republic of China Abstract: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the evidence-based first-line treatment for advanced non-small-cell lun...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-09-01
|
| Series: | OncoTargets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/osimertinib-making-a-breakthrough-in-lung-cancer-targeted-therapy-peer-reviewed-article-OTT |